Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18137793 | 0.87 | TDP1 (0.42) | TDP1ATMNPSR1MEN1KMT2A | |
| SCHEMBL5024804 | 0.82 | MEN1 (0.55) | TDP1ATMNPSR1MEN1KMT2A | |
| SCHEMBL14820488 | 0.81 | TDP1 (0.50) | TDP1ATMNPSR1MEN1KMT2A | |
| SCHEMBL14682808 | 0.80 | TDP1 (0.48) | TDP1ATMNPSR1MEN1KMT2A | |
| SCHEMBL25550092 | 0.80 | TDP1 (0.47) | TDP1ATMNPSR1MEN1KMT2A | |
| SCHEMBL30186579 | 0.78 | MEN1 (0.60) | TDP1ATMNPSR1MEN1KMT2A | |
| SCHEMBL26100889 | 0.78 | CAPN1 (0.46) | MEN1KMT2AGAACTSKCTSS | |
| SCHEMBL26100893 | 0.78 | CAPN1 (0.46) | MEN1KMT2AGAACTSKCTSS | |
| SCHEMBL16504665 | 0.77 | CTSS (0.53) | TDP1ATMNPSR1MEN1KMT2A | |
| SCHEMBL19975659 | 0.77 | TDP1 (0.50) | TDP1ATMNPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070095-B1 | ADENO-ASSOCIATED VIRUS WITH SITE-DIRECTED MUTAGENESIS AND SITE-DIRECTED MODIFICATION, AND PREPARATION METHOD AND APPLICATION THEREFOR | UNIV BEIJING (CN) | 2021-04-28 | — | — | EP | disclosed |
| US-20160297855-A1 | Adeno-Associated Virus with Site-Directed Mutagenesis and Site-Directed Modification and Preparation Method and Application Thereof | PEKING UNIVERSITY (CN) | 2016-10-13 | — | — | US | disclosed |
| EP-3070095-A1 | ADENO-ASSOCIATED VIRUS WITH SITE-DIRECTED MUTAGENESIS AND SITE-DIRECTED MODIFICATION, AND PREPARATION METHOD AND APPLICATION THEREFOR | Peking University (CN) | 2016-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297855-A1 | Adeno-Associated Virus with Site-Directed Mutagenesis and Site-Directed Modification and Preparation Method and Application Thereof | PHAX, VPS26B, ADAR | TDP1 2675/4885ATM 779/4885NPSR1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.